- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01287546
A Study of LY2875358 in Participants With Advanced Cancer
A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92037-0845
- University of California - San Diego
-
Los Angeles, California, United States, 90048-5615
- Cedars Sinai Medical Center
-
San Francisco, California, United States, 94115
- Univ of California San Francisco
-
Santa Monica, California, United States, 90404
- UCLA
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic of Jacksonville
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0946
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Mayo Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Part A: Have histological or cytological evidence of cancer (solid tumor, lymphoma, or multiple myeloma) that is advanced and/or metastatic and an appropriate candidate for experimental therapy
- Part A2: Histologic or cytologic diagnosis of advanced Non Small Cell Lung Cancer (NSCLC), Stage IIIB with malignant pleural effusion or Stage IV, completed at least 1 prior systemic regimen, and eligible for erlotinib therapy.
- Part B: Candidate for experimental therapy after standard therapies used or non-eligible for standard therapies. Histological or cytological evidence of 1 of the 5 tumor types:
Castrate-resistant prostate cancer (CRPC) with bone metastasis:
--Progressive Disease in the setting of castrate level of testosterone
Renal Cell Carcinoma (RCC):
--Histologic diagnosis of either clear-cell or papillary RCC (metastatic and unresectable, or bilateral, multifocal, unresectable RCC localized to kidneys).
NSCLC:
--Histologic or cytologic diagnosis of advanced NSCLC, Stage IIIB with malignant pleural effusion or Stage IV
Hepatocellular Carcinoma (HCC)
--Histologic or cytologic diagnosis of hepatocellular carcinoma
- Uveal Melanoma with liver metastasis
- Part A: Have the presence of measurable or nonmeasurable disease as defined by the RECIST v1.1 (Eisenhauer et al. 2009) or Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007) or have measureable disease for multiple myeloma.
- Part A2 & B (RCC, NSCLC, HCC, and uveal melanoma): Have measurable disease as defined by RECIST v1.1.
- Give written informed consent prior to any study-specific procedures.
- Adequate organ function.
- Performance status of less than or equal to 2 on ECOG scale.
- Discontinued all previous cancer therapies, and any agents that have not received regulatory approval, for at least 21 days and recovered from the acute effects of therapy. Must have discontinued mitomycin-C or nitrosourea therapy for at least 42 days.
- Reliable and available for the duration of the study and willing to follow study procedures.
- Males and females (reproductive potential): Use medically approved contraceptive precautions during the study and for 4 months following the last dose of study drug.
- Females (childbearing potential): Have had a negative serum pregnancy test before the first dose of study drug and not be breast-feeding.
- Estimated life expectancy that will permit the participants to complete 8 weeks of treatment.
Exclusion Criteria:
- Serious preexisting medical conditions
- Symptomatic central nervous system malignancy or metastasis (screening not required).
- Acute or chronic leukemia.
- Active infection including HIV, hepatitis A, B or C
- Have second primary malignancy that may affect the interpretation of results.
- Have received a liver transplant, or have liver cirrhosis with a Child-Pugh Stage of B or C.
- Patients with active alcohol abuse, as determined by the treating investigator.
- Part A2: Unable to swallow tablets. Intolerant of therapy with erlotinib. Concomitant treatment with the cytochrome P450 3A (CYP3A) modulators. Must not have received treatment with any of these modulators within 14 days of study treatment.
- Have a history of New York Heart Association class ≥3, unstable angina, myocardial infarction 6 months prior to study drug
- QTc greater than 470 msec.
- Received previous treatment with any c-MET experimental therapeutic.
Part B Expansion Cohort 1 (CRPC):
- Increasing use of daily doses of opioid analgesics within 28 days prior to enrollment in the study.
- Neuroendocrine prostate cancer.
- Patients who have a solitary bone metastasis that has been irradiated are not eligible.
- Part B Expansion Cohort 6 (LY2875358 plus trametinib in participants with uveal melanoma with liver metastasis): Contra-indications for trametinib
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY2875358
|
Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
|
Experimental: LY2875358 + erlotinib
|
Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
|
Experimental: LY2875358 at Part A highest dose
|
Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
|
Experimental: LY2875358 at Part A highest dose + trametinib
|
Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Recommended Phase 2 dose range of LY2875358 monotherapy and in combination with erlotinib
Time Frame: Baseline through Cycle 1
|
Baseline through Cycle 1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Maximum plasma concentration (Cmax)
Time Frame: Days 1, 2, 4, 5, 6, 8, 15, and 22 of Cycle 1. Days 1, 15, and 22 of Cycle 2. Days 1 and 15 of Cycles 3 and beyond, as well as 14 days, 29 days, and 57 days following the final treatment
|
Days 1, 2, 4, 5, 6, 8, 15, and 22 of Cycle 1. Days 1, 15, and 22 of Cycle 2. Days 1 and 15 of Cycles 3 and beyond, as well as 14 days, 29 days, and 57 days following the final treatment
|
Number of participants with a tumor response
Time Frame: Baseline to study completion (12 months)
|
Baseline to study completion (12 months)
|
Pharmacokinetics: Area under the concentration-time curve (AUC)
Time Frame: Days 1, 2, 4, 5, 6, 8, 15, and 22 of Cycle 1. Days 1, 15, and 22 of Cycle 2. Days 1 and 15 of Cycles 3 and beyond, as well as 14 days, 29 days, and 57 days following the final treatment
|
Days 1, 2, 4, 5, 6, 8, 15, and 22 of Cycle 1. Days 1, 15, and 22 of Cycle 2. Days 1 and 15 of Cycles 3 and beyond, as well as 14 days, 29 days, and 57 days following the final treatment
|
Time to progression and overall survival
Time Frame: Baseline to study completion (12 months)
|
Baseline to study completion (12 months)
|
Pharmacokinetics: Area under the concentration-time curve (AUC) of erlotinib or trametinib in combination with LY2875358
Time Frame: Cycle 1
|
Cycle 1
|
Change from baseline in Brief Pain Inventory (BPI) in Part B: Expansion Cohort 1
Time Frame: Baseline to study completion (12 months)
|
Baseline to study completion (12 months)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13298
- I4C-MC-JTBA (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
University Health Network, TorontoUniversity of UlmRecruiting
Clinical Trials on LY2875358
-
Eli Lilly and CompanyCompletedGastric CancerJapan, Korea, Republic of
-
Eli Lilly and CompanyCompletedRenal Cell Carcinoma | Non-Small Cell Lung Cancer | Gastric Adenocarcinoma | Advanced Cancer | Hepatocellular Cancer | Gastroesophageal Junction AdenocarcinomaUnited States
-
Eli Lilly and CompanyActive, not recruitingCarcinoma, Non-Small-Cell LungSpain, Taiwan, United Kingdom, France, Germany, Netherlands, Korea, Republic of, Italy, Denmark
-
Eli Lilly and CompanyCompletedCarcinoma, Non-Small-Cell LungUnited States, Germany, Spain, Belgium, France, United Kingdom, Netherlands, Italy, Israel, Korea, Republic of
-
Eli Lilly and CompanyCompletedLymphoma | Carcinoma, Non-Small-Cell Lung | Solid TumorsJapan